" class="no-js "lang="en-US"> Johnson & Johnson Appoints Executive VP, Pharmaceuticals, R&D
Friday, March 31, 2023

Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D

Johnson & Johnson has announced the appointment of John Reed, to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the Company.

Dr. Reed will join Johnson & Johnson on April 3, 2023, assuming responsibility for the Company’s industry-leading portfolio from William Hait, who has served as interim head of Johnson & Johnson’s Pharmaceutical R&D organization since August 2022.

Joaquin Duato, Chairman of the Board and Chief Executive Officer of Johnson & Johnson commented, “Dr. Reed is an accomplished leader and highly regarded researcher with an extraordinary track record for discovering and developing life-saving innovations on a global scale. I am confident his experience and leadership will enable our Pharmaceutical R&D organization to continue to accelerate innovation and competitiveness, invest with focus and discipline and improve the lives of the patients we serve around the world with transformational medicines.”

Dr. Reed, Executive Vice President, Pharmaceuticals, R&D, said, “I am deeply honored and extremely excited to join Johnson & Johnson. I share the Company’s commitment to innovation to conquer disease and improve human health, and I look forward to applying my passion for science, experience in drug discovery and development and commitment to helping patients in leading the talented Pharmaceutical R&D team.”

Companies In This Post

  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) Read more